clinical trial · NCT05889273
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
Autism Spectrum DisorderML-004 (IR)/(ER) tablet
brief summary
ML-004-003 is a multi-center, open-label extension study that will enroll approximately 120 adolescent and adult subjects with ASD that have completed study ML-004-002. The primary objective of the study will be to evaluate the safety of ML-004 in subjects with ASD.
started
Jun 1, 2023
primary completion
Nov 1, 2027
completion
Dec 1, 2027
last updated
Mar 16, 2026
official title
An Open-label Extension Study to Investigate Safety and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol